Marina Vladimirovna Ryzhova

Marina Vladimirovna Ryzhova

Auto-generated profile, based on publicly available information

Marina Vladimirovna Ryzhova

N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2018 in Nature
Verified
Journal Article
Open access
PDF file
DCDavid Capper
David Capper
DJDavid T. W. Jones
David T. W. Jones
MSMartin Sill
Martin Sill
VHVolker Hovestadt
Volker Hovestadt
DSDaniel Schrimpf
Daniel Schrimpf
SPStefan M. Pfister
Stefan M. Pfister
Accurate pathological diagnosis is crucial for optimal management of patients with cancer. For the approximately 100 known tumour types of the central nervous system, standardization of the diagnostic process has been shown to be particularly challenging—with substantial inter-observer variability in the histopathological diagnosis of many tumour types. Here we present a comprehensive approach for the DNA methylation-based classification of central nervous system tumours across all entities and age groups, and demonstrate its application in a routine diagnostic setting. We show that the availability of this method may have a substantial impact on diagnostic precision compared to standard methods, resulting in a change of diagnosis in up to 12% of prospective cases. For broader accessibility, we have designed a free online classifier tool, the use of which does not require any additional onsite data processing. Our results provide a blueprint for the generation of machine-learning-based tumour classifiers across other cancer entities, with the potential to fundamentally transform tumour pathology.

29 January 2012 in Nature
Verified
Journal Article
Closed access
PDF file
JSJeremy Schwartzentruber
Jeremy Schwartzentruber
Andrey KorshunovAndrey Korshunov
Andrey Korshunov
XLXiao-Yang Liu
Xiao-Yang Liu
DJDavid T. W. Jones
David T. W. Jones
EPElke Pfaff
Elke Pfaff
NJNada Jabado
Nada Jabado

1 October 2012 in Cancer Cell
Verified
Journal Article
Closed access
DSDominik Sturm
Dominik Sturm
HWHendrik Witt
Hendrik Witt
VHVolker Hovestadt
Volker Hovestadt
DKDong-Anh Khuong-Quang
Dong-Anh Khuong-Quang
DJDavid T.W. Jones
David T.W. Jones
Stefan PfisterStefan Pfister
Stefan Pfister

1 May 2015 in Cancer Cell
Verified
Journal Article
Closed access
Kristian W. PajtlerKristian W. Pajtler
Kristian W. Pajtler
HWHendrik Witt
Hendrik Witt
MSMartin Sill
Martin Sill
DJDavid T.W. Jones
David T.W. Jones
VHVolker Hovestadt
Volker Hovestadt
Stefan PfisterStefan Pfister
Stefan Pfister

20 July 2017 in Nature
Verified
Journal Article
Open access
PDF file
PNPaul A. Northcott
Paul A. Northcott
IBIvo Buchhalter
Ivo Buchhalter
AMA. Sorana Morrissy
A. Sorana Morrissy
VHVolker Hovestadt
Volker Hovestadt
JWJoachim Weischenfeldt
Joachim Weischenfeldt
PLPeter Lichter
Peter Lichter
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma.

1 February 2016 in Cell
Verified
Journal Article
Closed access
DSDominik Sturm
Dominik Sturm
BOBrent A. Orr
Brent A. Orr
UTUmut H. Toprak
Umut H. Toprak
VHVolker Hovestadt
Volker Hovestadt
DJDavid T.W. Jones
David T.W. Jones
MKMarcel Kool
Marcel Kool